The company's portfolio of diagnostic tests covers key cancer types and is supported by €3.9m in EU R&D funding, with 12 employees funded through 6 grants. Led by Dr. Mairin Rafferty, the CEO/COO, OncoMark has a strong advisory board and focuses on the development and application of biomarker panels to support oncology drug development, including unique multi-marker assays and novel image analysis tools.